NAUT Nautilus Biotechnology, Inc.
USHealthcareAs of 2026-08-24
Why NAUT matters now
Nautilus Biotechnology, Inc. (NAUT) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.88 with -8.30% on the session and $111.4M in market capitalization; recent performance reads 1-month -4.20% and YTD +16.92%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-14.7M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.7%.
The latest indexable market news headline is "Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.50; recent insider activity includes AH Equity Partners Bio II, L.L.C. filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.00
P/S
0.00
EV/EBITDA
-5.99
DCF Value
$-0.15
FCF Yield
-17.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.0%
ROA
-32.1%
ROIC
-37.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-14.7M | $-0.12 |
| Q4 2025 | $0.00 | $-13.8M | $-0.11 |
| FY 2025 | $0.00 | $-59.0M | $-0.47 |
| Q3 2025 | $0.00 | $-13.6M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.50
Target (Median)
$2.50
Target Range
$2.50 - $2.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.75
Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus Platform, is an integrated proteomics system. It provides a complete, end-to-end solution, including specialized instruments, essential consumables, and advanced software for data analysis. Based in Seattle, Washington, the company was established in 2016.